LC53-0151

LC53-0151 is a small molecule, orally bioavailable proteasome inhibitor developed by LG Chem (formerly LG Life Sciences) for the treatment of multiple myeloma. It is an analog of LC53-0110 and functions by specifically targeting the chymotrypsin-like proteolytic (β5) site of the 20S proteasome. Preclinical research has demonstrated that LC53-0151 exhibits potent cytotoxic effects on multiple myeloma cell lines, such as MM.1S, and shows synergistic anti-tumor activity when combined with the immunomodulatory drug pomalidomide. The compound was designed to provide improved efficacy and safety profiles compared to first- and second-generation proteasome inhibitors like bortezomib, carfilzomib, and ixazomib.